Page 169 - Screening for Cervical Cancer: Systematic Evidence Review
P. 169
Chapter III: Results
Table 7. Studies with Screening Uses of HPV* Testing
Prevalence of Prevalence of Prevalence of
Article Population LSIL (%) HSIL (%) Carcinoma (%)
Cuzick et 2,988 women age ≥ 34 HPV/borderline = 1.9; CIN 2 = 0.3
§
21
§
§
al., 1999 presenting for routine Pap CIN 1 = 0.9 CIN 3 = 1.1 No cases
screening in UK
§
Petry et al., 138 HIV infected women CIN 1 = 14.5 CIN 2 = 3.6 Invasive Ca = 2.2
ll
§
§
61
1999 CIN 3 = 6.5
Schiffman 8,554 Costa Rican women from Equivocal = 7.7;
ll
et al., random door-to-door selection LSIL = 2.2 HSIL = 1.5 Invasive Ca = 0.14
65
2000
Womack et 466 women age 25-55 in
63
al., 2000 primary care clinics in Zimbabwe LSIL = 12.9 HSIL = 12.0 No cases
Womack et 2,140 women age 25-55 in LSIL = 16.2 HSIL = 10.0 Invasive Ca = 0.14
ll
62
al., 2000 primary care clinics in Zimbabwe
Wright et 1,365 unscreened women, age ≥ ll
64
al., 2000 35 from clinics in South Africa LSIL = 2.9 HSIL = 3.4 Invasive Ca = 0.7
* HPV, human papilloma virus.
LSIL, low-grade squamous intraepithelial lesion.
HSIL, high-grade squamous intraepithelial lesion.
§ CIN, cervical intraepithelial neoplasia.
ll Invasive Ca, invasive cancer.
70
